TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Operating Margin
- Operating margin · 12 months: Value -568.43%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -568.43% | Operating income / revenue. Period ending 2026-06-30. $-165.43M ÷ $29.10M × 100 ≈ -568.43% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -165.43M USD | Operating Income (Loss) |
| Revenue | 29.10M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 63.86M USD | Research and Development Expense |
| Selling, general and administration | 125.96M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-165.43M | $29.10M | (m) | $63.86M | $125.96M | -568.43% |
| 2026-03-31 | $-151.19M | $17.56M | (m) | $55.26M | $106.20M | -861.16% |
| 2025-12-31 | $-125.70M | $13.11M | (m) | $44.49M | $87.68M | -959.05% |
| 2025-09-30 | $-99.90M | $10.30M | (m) | $35.84M | $67.59M | -969.97% |
| 2025-06-30 | $-82.38M | $9.83M | (m) | $35.67M | $49.59M | -838.00% |
| 2025-03-31 | $-131.40M | $10.04M | (m) | $34.55M | $40.90M | -1308.67% |
| 2024-12-31 | $-136.70M | $10.09M | (m) | $39.97M | $40.10M | -1354.28% |
| 2024-09-30 | $-141.55M | $11.29M | (m) | $48.80M | $36.14M | -1253.65% |
| 2024-06-30 | $-154.14M | $12.46M | (m) | $60.73M | $37.15M | -1237.30% |
| 2024-03-31 | $-105.83M | (m) | (m) | $73.01M | $36.67M | (m) |
| 2023-12-31 | $-118.38M | $7.77M | (m) | $86.66M | $34.75M | -1523.94% |
| 2023-09-30 | $-123.78M | (m) | (m) | $94.21M | (m) | (m) |
| 2023-06-30 | $-125.22M | (m) | (m) | $95.36M | (m) | (m) |
| 2023-03-31 | $-119.56M | (m) | (m) | $89.97M | (m) | (m) |
| 2022-12-31 | $-112.09M | (m) | (m) | $81.88M | (m) | (m) |
| 2022-09-30 | $-108.84M | (m) | (m) | $79.50M | (m) | (m) |
| 2022-06-30 | $-97.79M | (m) | (m) | $70.38M | (m) | (m) |
| 2022-03-31 | $-98.01M | (m) | (m) | $71.93M | (m) | (m) |
| 2021-12-31 | $-92.31M | (m) | (m) | $68.84M | (m) | (m) |
| 2021-09-30 | $-79.86M | (m) | (m) | $58.64M | (m) | (m) |
| 2021-06-30 | $-73.32M | (m) | (m) | $54.37M | (m) | (m) |
| 2021-03-31 | $-63.95M | (m) | (m) | $46.81M | (m) | (m) |
| 2020-12-31 | $-50.51M | (m) | (m) | $36.16M | (m) | (m) |
| 2020-09-30 | $-42.22M | (m) | (m) | $29.75M | (m) | (m) |
| 2020-06-30 | $-38.11M | (m) | (m) | $25.99M | (m) | (m) |
| 2020-03-31 | $-29.83M | (m) | (m) | $18.97M | (m) | (m) |
| 2019-12-31 | $-28.83M | (m) | (m) | $18.19M | (m) | (m) |
| 2019-09-30 | $-27.74M | (m) | (m) | $17.56M | (m) | (m) |
| 2019-06-30 | $-25.39M | (m) | (m) | $15.77M | (m) | (m) |
| 2019-03-31 | $-25.63M | (m) | (m) | $16.28M | (m) | (m) |
| 2018-12-31 | $-26.32M | (m) | (m) | $17.56M | (m) | (m) |
| 2018-09-30 | $-24.21M | (m) | (m) | $16.14M | (m) | (m) |
| 2018-06-30 | $-24.51M | (m) | (m) | $16.78M | (m) | (m) |
| 2018-03-31 | $-23.19M | (m) | (m) | $15.52M | (m) | (m) |
| 2017-12-31 | $-21.29M | (m) | (m) | $13.34M | (m) | (m) |
| 2017-09-30 | $-23.26M | (m) | (m) | $14.59M | (m) | (m) |
| 2017-06-30 | $-25.03M | (m) | (m) | $16.15M | (m) | (m) |
| 2017-03-31 | $-30.05M | (m) | (m) | $20.86M | (m) | (m) |
| 2016-12-31 | $-38.97M | (m) | (m) | $28.53M | (m) | (m) |
| 2016-09-30 | $-44.86M | (m) | (m) | $33.14M | (m) | (m) |
| 2016-06-30 | $-50.53M | (m) | (m) | $37.99M | (m) | (m) |
| 2016-03-31 | $-52.48M | (m) | (m) | $39.35M | (m) | (m) |
| 2015-12-31 | $-48.16M | (m) | (m) | $35.50M | (m) | (m) |
| 2015-09-30 | $-43.76M | (m) | (m) | $31.79M | (m) | (m) |
| 2015-06-30 | $-37.92M | (m) | (m) | $26.69M | (m) | (m) |
| 2015-03-31 | $-32.18M | (m) | (m) | $21.90M | (m) | (m) |
| 2014-12-31 | $-27.66M | (m) | (m) | $18.62M | (m) | (m) |
| 2014-09-30 | $-22.36M | (m) | (m) | $14.17M | (m) | (m) |
| 2014-06-30 | $-18.02M | (m) | (m) | $10.59M | (m) | (m) |
| 2014-03-31 | $-14.06M | (m) | (m) | $7.46M | (m) | (m) |
| 2013-12-31 | $-10.89M | (m) | (m) | $4.65M | (m) | (m) |
| 2013-09-30 | $-9.09M | (m) | (m) | $4.02M | (m) | (m) |
| 2013-06-30 | $-7.74M | (m) | (m) | $3.04M | (m) | (m) |
| 2013-03-31 | $-7.50M | (m) | (m) | $2.93M | (m) | (m) |
| 2012-12-31 | $-6.66M | (m) | (m) | $2.58M | (m) | (m) |
| 2012-09-30 | $-6.24M | (m) | (m) | $2.41M | (m) | (m) |
| 2012-06-30 | $-5.52M | (m) | (m) | $2.24M | (m) | (m) |
| 2012-03-31 | $-4.03M | (m) | (m) | $1.48M | (m) | (m) |
| 2011-12-31 | $-3.38M | (m) | (m) | $1.16M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-1.93M | (m) | (m) | $584.30K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |